Propofol for palliative sedation: A systematic review of clinical outcomes, safety, and ethical implications
Luís Almeida-Jardim, Paulo Reis-PinaBackground:
Palliative sedation is used to relieve refractory suffering in terminally ill patients. Propofol, an intravenous anesthetic, may offer advantages due to its rapid onset and short half-life.
Aim:
To evaluate the role of propofol in palliative sedation, focusing on symptom control, sedation depth, survival time, safety, and ethical implications.
Design:
Systematic review registered in PROSPERO (CRD42025643575; February 6, 2025).
Data sources:
Scopus, MEDLINE, and Web of Science were searched for English-language studies (2005–2024) on propofol use in adult terminally ill patients. Studies comparing propofol with other sedatives or non-sedated controls were included; those involving anesthetic or intensive care settings were excluded. Risk of bias and certainty of evidence were assessed. Results were synthesized narratively.
Results:
Ten non-randomized studies were included (observational, cross-sectional, cohort, case series, and before-and-after designs), mostly of moderate quality, conducted in Europe (
Conclusions:
Propofol may be considered as a rescue option in selected refractory cases managed by experienced teams; however, given the low to very low certainty of available evidence, findings should be interpreted cautiously and supported by institutional protocols and further prospective research.